JPH05239004A - ロイコトリエンｂ４拮抗物質 - Google Patents

ロイコトリエンｂ４拮抗物質

Info

Publication number
JPH05239004A
JPH05239004A JP4164065A JP16406592A JPH05239004A JP H05239004 A JPH05239004 A JP H05239004A JP 4164065 A JP4164065 A JP 4164065A JP 16406592 A JP16406592 A JP 16406592A JP H05239004 A JPH05239004 A JP H05239004A
Authority
JP
Japan
Prior art keywords
group
lower alkyl
chr
coor
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4164065A
Other languages
English (en)
Japanese (ja)
Inventor
Hideo Nagata
英夫 永田
Hajime Kawakami
肇 川上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of JPH05239004A publication Critical patent/JPH05239004A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP4164065A 1991-05-31 1992-05-28 ロイコトリエンｂ４拮抗物質 Pending JPH05239004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3-157725 1991-05-31
JP15772591 1991-05-31

Publications (1)

Publication Number Publication Date
JPH05239004A true JPH05239004A (ja) 1993-09-17

Family

ID=15656005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4164065A Pending JPH05239004A (ja) 1991-05-31 1992-05-28 ロイコトリエンｂ４拮抗物質

Country Status (13)

Country Link
US (1) US5225422A (enExample)
EP (1) EP0516069B1 (enExample)
JP (1) JPH05239004A (enExample)
KR (1) KR920021534A (enExample)
AT (1) ATE137223T1 (enExample)
AU (1) AU643140B2 (enExample)
CA (1) CA2069667A1 (enExample)
DE (1) DE69210091T2 (enExample)
DK (1) DK0516069T3 (enExample)
ES (1) ES2086579T3 (enExample)
GR (1) GR3020050T3 (enExample)
MX (1) MX9202612A (enExample)
TW (1) TW204343B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503552A (ja) * 2000-06-13 2004-02-05 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト ヘタリール−置換複素環式化合物
JP2008520680A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
DE10257785A1 (de) * 2002-12-11 2004-07-01 Bayer Healthcare Ag Isophthalsäurederivate
AU2011226942B2 (en) * 2004-11-22 2012-06-28 Eli Lilly And Company Potentiators of glutamate receptors
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
BRPI0610506A2 (pt) 2005-04-20 2010-06-29 Johnson & Johnson moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) * 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666928A (en) * 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
US4672066A (en) * 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
CA1315279C (en) * 1987-01-12 1993-03-30 Nancy Grace Bollinger Anti-inflammatory agents
JPS6429363A (en) * 1987-07-23 1989-01-31 Yoshitomi Pharmaceutical Heterocyclic derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503552A (ja) * 2000-06-13 2004-02-05 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト ヘタリール−置換複素環式化合物
JP2008520680A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤
JP2008520676A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤

Also Published As

Publication number Publication date
ATE137223T1 (de) 1996-05-15
DK0516069T3 (da) 1996-05-13
AU1719392A (en) 1993-03-11
GR3020050T3 (en) 1996-08-31
MX9202612A (es) 1992-11-01
DE69210091T2 (de) 1996-10-02
AU643140B2 (en) 1993-11-04
DE69210091D1 (de) 1996-05-30
TW204343B (enExample) 1993-04-21
EP0516069B1 (en) 1996-04-24
KR920021534A (ko) 1992-12-18
ES2086579T3 (es) 1996-07-01
US5225422A (en) 1993-07-06
CA2069667A1 (en) 1992-12-01
EP0516069A1 (en) 1992-12-02

Similar Documents

Publication Publication Date Title
AU779550B2 (en) Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
AU725403B2 (en) Thrombin inhibitors
EP0706524B1 (en) Processes and intermediates for the preparation of 5- 2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0503627A1 (en) Aminopyridine compounds
CA1339645C (en) Pyridinium derivatives, their production and use
EP0516069A1 (en) Leukotriene B4 antagonist
JPH05508841A (ja) 心臓血管活性を有する安息香酸置換誘導体
RO118428B1 (ro) DERIVATI DE IMIDAZO[1,2-a]PIRIDINE ALCOXIALCHILCARBAMATI, PROCEDEE DE PREPARARE ALE ACESTORA SI COMPOZITIE FARMACEUTICA CARE II CONTINE
CA2240594C (en) 2,7-substituted octahydro-pyrrolo¬1,2-a|pyrazine derivatives
US5534515A (en) Pyrrolopyridazines having gastrointestinal protective effects
JPS62209062A (ja) ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
US4348396A (en) Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them
JPS6354363A (ja) キノリン誘導体
JP2661892B2 (ja) Ｎ−アリールアルキルフェニルアセトアミド化合物
JPH01117882A (ja) 複素環式カルボン酸アミド誘導体
JPS63179869A (ja) ピペリジン誘導体
LT3798B (en) Method for the preparation of n,n'-bis(alkoxyalkyl)-pyrimidine-2,4-dicarboxylic acids diamides and use thereof
CN118108704A (zh) Kif18a抑制剂
JP3207018B2 (ja) ベンジルコハク酸誘導体の製造方法およびその製造中間体
GB2092130A (en) 4-Oximino-1,2,3,4- tetrahydroquinoline Derivatives
US3974282A (en) Hypoglycemic stilbazolte derivatives
JPH01308227A (ja) プロテアーゼ阻害剤
US5380748A (en) Trialkylamine derivative and ameliorant for digestive tract movement containing the same
KR880001067B1 (ko) 페닐알칸산 유도체의 제조방법
KR810002003B1 (ko) 피리도[2, 1-b] 퀴나졸린 유도체의 제조방법